

**Correspondence on “Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment” by Felson et al.**

Ricardo J. O. Ferreira, PhD<sup>1,2</sup>, Paco M. J. Welsing, PhD<sup>3</sup>, Johannes W. G. Jacobs, PhD<sup>4</sup>, Laure Gossec, PhD<sup>5,6</sup>, Mwidimi Ndosì, PhD<sup>7</sup>, Pedro M. Machado, PhD<sup>8,9,10</sup>, Désirée van der Heijde, PhD<sup>11</sup>, José A. P. da Silva, PhD<sup>1,12</sup>

1 – Rheumatology department – Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

2 – Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra, Coimbra, Portugal; rferreira@reumahuc.org

3 – Department of Rheumatology & Clinical Immunology – University Medical Center, Utrecht, The Netherlands; P.M.J.Welsing@umcutrecht.nl

4 – Department of Rheumatology & Clinical Immunology – University Medical Center, Utrecht, The Netherlands; J.W.G.Jacobs@umcutrecht.nl

5 – Sorbonne Université – Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Paris France

6 – Rheumatology department – Pitié Salpêtrière hospital, AP-HP, Paris, France. laure.gossec@gmail.com

7 – School of Health and Social Wellbeing – University of the West of England, Bristol, UK; mwidimi.ndosi@uwe.ac.uk

8 – Centre for Rheumatology & Department of Neuromuscular Diseases – University College London, London, UK

9 – Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK

10 – Department of Rheumatology – Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK; p.machado@ucl.ac.uk

11 – Rheumatology department – Leiden University Medical Centre, Leiden, The Netherlands; mail@dvanderheijde.nl

12 – Clínica Universitária de Reumatologia, and i-CBR Coimbra Institute for Clinical and Biological Research, Faculty of Medicine - University of Coimbra, - Portugal; jdasilva@chuc.min-saude.pt

**Corresponding author:** José António P. da Silva, MD, PhD

Rheumatology Department, Centro Hospitalar Universitário de Coimbra, EPE.

Praceta Professor Mota Pinto, 3000-075 Coimbra. Portugal

Phone: 00351 239400547 Fax: 00351 239400587 e-mail: [jasilva@chuc.min-saude.pt](mailto:jasilva@chuc.min-saude.pt)

**Word count:** 960

**Competing interests:** none to disclose.

**Contributorship:** José A. P. da Silva wrote the first draft of the manuscript and all authors have reviewed it and agreed with the final version.

**Acknowledgements:** not applicable.

**Funding, grant/award info:** There are no funders to report for this submission.

**Ethical approval information:** not applicable.

**Data sharing statement:** not applicable.

**Patient and Public Involvement:** The group of authors of this letter is the same as the article cited in the Editorial we are now corresponding to. Although no patient or public was involved in the current manuscript, they were part of the research team and authors of several other papers on the topic of the “Dual Target Strategy”.

Dear Editor:

We read with great interest the editorial by Felson et al. on definitions of remission in rheumatoid arthritis (RA).[1] It gives a comprehensive and historical overview of the development of remission criteria, and provides a well-founded critique of remission criteria based on the 28-joint Disease Activity Score (DAS28). DAS28 has been primarily developed and validated for evaluations at the group level, i.e. for measuring effects in clinical trials. However, in almost forgotten earlier times, when patient remission was rarely achieved, there was a need for a single index, expressing disease activity of the individual patient, and the only instrument available was the 44-joint Disease Activity Score (DAS).[2] When biologicals become available, in many countries of Europe, use of DAS28 as single index of disease activity was also stimulated by health authorities and insurance companies, requiring DAS28 proof of active RA and documented previous treatment failure (or contra-indication) of conventional synthetic DMARDs, before allowing reimbursement of an (expensive) biological drug. Since then, remission has proved to be an achievable goal, and for clinical trials and for individual patients, DAS28 cut-offs have been used for this purpose, especially in Europe, although their limitations for evaluations at the individual patient level have indeed been recognised.[3]

Moreover, we agree with Felson et al. that patient global assessment (PGA) is a valuable assessment. However, we feel compelled to clarify the misunderstanding that seems to persist regarding our relatively simple proposal. We do not suggest merely eliminating PGA from the definitions of remission; we suggest that a second target, based on valid and discriminative patient-reported measures of disease impact, is adopted, in parallel but separated from the existing target for (inflammatory) disease activity, which, we believe, could be refined by the exclusion of PGA. Although Felson et al. cite our paper,[4] they do not depict our proposal for this “Dual Target Strategy” and its conceptual framework, summarized in the conclusions of that paper. Following our proposal, the patient’s perspective would become more valued, rather than being ignored.

We disagree with the interpretation of the evidence provided by Felson et al. to support the concept that PGA should be kept as a component of the ACR/EULAR definitions of remission. Although PGA and measures of clinical disease activity are correlated at high levels of disease activity, contributing to the ability of PGA to distinguish active treatment from placebo in the context of clinical trials, they are only poorly, if at all, correlated at low levels of disease activity,[5, 6] precisely when the practising clinician needs to make difficult decisions regarding escalating or maintaining immunosuppressive/immunomodulatory therapy. Thus, while the inclusion of PGA may facilitate the distinction between treatments in clinical trials, we are concerned regarding the implications of including PGA as an element of composite definitions of remission used to tailor immunosuppressive/immunomodulatory therapy in clinical practice and the potential risk of

overtreatment that this entails. As many as 45 to 61% of all patients with RA (in clinical trials[4] and cohort studies,[7] respectively) who are otherwise in remission fail to meet the Boolean definition of remission, solely because of a too high PGA score. These patients, in so-called “PGA-near-remission”, are exposed to the risk of overtreatment, because their disease cannot be improved by additional immunosuppression/immunomodulation. However, they still endure significant impact of non-disease activity manifestations and outcomes of the disease,[8] which were recently touched upon in the EULAR points to consider for the management of difficult-to-treat RA.[9] The use of the ACR/EULAR remission definitions in clinical practice was explicitly predicted in the original 2011 report,[10] and has been extensively adopted as part of the Treat-to-Target strategy. Thus, the implications of these definitions are more extensive than those for clinical trials only.

The assertion that PGA reflects subclinical inflammation is, in our view, unsupported by evidence. We, and in fact, some of the authors of the editorial themselves, have shown no correlation between PGA and joint damage accrual.[11] We have also demonstrated that in patients that are in PGA-near-remission there is no evidence of inflammation in other joints or synovial structures, through extensive ultrasonography assessment.[12] It is difficult to envisage what room is left for the consideration in the editorial that “...*the patient global assessment reflects components of disease activity that are otherwise not captured, ...as inflammation in joints not included in a 28-joint count, such as the feet and ankles.*” This is, therefore, not the reason “*why high patient global assessment scores, even when 28-joint counts are low, identify patients at high risk of later functional loss.*”[1] This may be simply and better explained by the fact that function is a major determinant of PGA, irrespective of (inflammatory) disease activity, as repeatedly reported.[5, 6, 8, 13] These publications are the basis of our “Dual Target Strategy” proposal, which we hypothesize, may result in more accurate and comprehensive definitions of remission. We proposed the “Dual Target” to comprise (i) biologic remission, which will be sharper and more sensitive to help guide immunosuppressive/immunomodulatory therapy in individual patients in clinical practice, and (ii) patient remission, addressing also all other important aspects of non-disease activity manifestations, outcomes of the disease, and of medication adverse effects (disease impact); thus, more informative than the current one-item PGA. Surely, this approach highlights the importance of patients’ perspective as it ensures that clinicians address both the disease activity and the disease impact aspects accordingly.

In summary, we agree with many of the points made in the editorial by Felson et al., but we feel that it distorts our proposal by omitting to mention the patient remission aspect, which is what makes it a “Dual Target”: a holistic strategy that empowers patients and promotes health by allowing patients to

gain greater control over decisions and actions affecting their health, a World Health Organization recommendation, since the Ottawa conference in 1986.

## References

1. Felson D, Lacaille D, LaValley MP, et al. Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment. *Annals of the Rheumatic Diseases*. 2021;10.1136/annrheumdis-2021-221653:annrheumdis-2021-221653.
2. van der Heijde DM, van 't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. *Ann Rheum Dis*. 1990;49:916-20.
3. Jacobs JW, Ten Cate DF, van Laar JM. Monitoring of rheumatoid arthritis disease activity in individual patients: still a hurdle when implementing the treat-to-target principle in daily clinical practice. *Rheumatology (Oxford)*. 2015;54:959-61.
4. Ferreira RJO, Welsing PMJ, Jacobs JW, et al. Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. *Ann Rheum Dis*. 2020;80:293-303.
5. Ferreira RJO, Duarte C, Ndosu M, et al. Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. *Arthritis Care Res (Hoboken)*. 2018;70:369-78.
6. Ferreira RJO, Carvalho PD, Ndosu M, et al. Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database. *Arthritis Care Res (Hoboken)*. 2019;71:1317-25.
7. Ferreira RJO, Santos E, Gossec L, et al. The patient global assessment in RA precludes the majority of patients otherwise in remission to reach this status in clinical practice. Should we continue to ignore this? *Semin Arthritis Rheum*. 2020;50:583-5.
8. Ferreira RJO, Dougados M, Kirwan JR, et al. Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. *Rheumatology (Oxford)*. 2017;56:1573-8.
9. Nagy G, Roodenrijs NMT, Welsing PMJ, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. *Ann Rheum Dis*. 2021;10.1136/annrheumdis-2021-220973.
10. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. *Ann Rheum Dis*. 2011;70:404-13.
11. Studenic P, Felson D, de Wit M, et al. Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal? *Ann Rheum Dis*. 2020;10.1136/annrheumdis-2019-216529.
12. Brites L, Rovisco J, Costa F, et al. High patient global assessment scores in patients with rheumatoid arthritis otherwise in remission do not reflect subclinical inflammation. *Joint Bone Spine*. 2021;88:105242.
13. Craig ET, Perin J, Zeger S, et al. What Does the Patient Global Health Assessment in Rheumatoid Arthritis Really Tell Us? Contribution of Specific Dimensions of Health-Related Quality of Life. *Arthritis Care Res (Hoboken)*. 2020;72:1571-8.